Julia Driessen
5PUBLICATIONS
26CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Mar 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.Julia Driessen, Fer de Wit, Alex F Herrera
|Sep 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.Julia Driessen, Gerben J C Zwezerijnen, Heiko Schöder
|Oct 14, 2022
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.Julia Driessen, Marie José Kersten, Lydia Visser
|Sep 02, 2022
Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma.Esther E E Drees, Julia Driessen, Gerben J C Zwezerijnen
|May 29, 2020
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.Julia Driessen, Otto Visser, Josée M Zijlstra
Pageof 1
Frequent Collaborators
3 joint publications
Josée M Zijlstra
2 joint publications
Esther E E Drees
2 joint publications
Gerben J C Zwezerijnen
2 joint publications
Jakoba J Eertink
2 joint publications
Ronald Boellaard
2 joint publications
Marie José Kersten
2 joint publications
Heiko Schöder
1 joint publications
Avinash G Dinmohamed
1 joint publications
Daphne de Jong
1 joint publications
Henrica C W de Vet
